CGM market seen reaching $18.86 billion by 2030

The continuous glucose monitoring market is projected to grow from $9.44 billion in 2025 to $18.86 billion by 2030, driven by rising diabetes rates, wearable sensor advances and broader home monitoring use. North America led in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Continuous glucose monitoring is becoming a core tool for diabetes care as more patients and providers move away from finger-prick testing. - The market’s growth reflects rising diabetes prevalence, stronger demand for real-time data and expanding use of remote care. - The Business Research Company’s report points to a $18.85 billion opportunity across the market outlook.

What happened: - The Business Research Company published a 2026 report on the global continuous glucose monitoring market. - The market is projected to rise from $9.44 billion in 2025 to $10.87 billion in 2026. - The report forecasts the market will reach $18.86 billion by 2030. - The report describes a 15.1% CAGR for the 2025-2026 period and a 14.8% CAGR through 2030. - Download a free sample of the continuous glucose monitoring market report - View the full continuous glucose monitoring market report

The details: - CGM systems use a small sensor placed just under the skin to track glucose levels continuously through the day and night. - The technology gives users alerts for high or low blood sugar and supports changes in diet, medication and lifestyle. - The report ties recent growth to limited early access to real-time glucose monitors, high initial device costs, low awareness in some markets, reliance on traditional finger-prick tests and broader hospital adoption. - The forecast period is expected to benefit from wearable and implantable sensor advances, mobile health app integration, telemedicine use, non-invasive glucose monitoring development and wider home healthcare access. - The report highlights rising demand for minimally invasive sensors, real-time analytics, alert systems and products designed for pediatric and elderly patients. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.

Between the lines: - Rising diabetes and pre-diabetes counts are expanding the addressable base for CGM devices. - The shift toward remote care suggests CGM growth is tied not just to clinical need, but to digital health workflows and home-based monitoring. - The report’s regional split points to a mature adoption story in North America and a faster adoption runway in Asia-Pacific. - The Business Research Company cited UK National Health Service data showing 3,615,330 people with non-diabetic hyperglycemia or pre-diabetes registered with general practitioners in 2023, up 18% from 3,065,825 in 2022.

What's next: - The market is expected to keep expanding as non-invasive sensing improves and telehealth becomes more embedded in diabetes management. - CGM adoption is likely to widen among patients managing chronic blood sugar conditions, especially in home-care settings. - Future demand is also likely to come from pediatric and elderly-focused monitoring tools. - The report says broader use of real-time analytics and alert systems will be a key trend through 2030.

The bottom line: - CGM is moving from a specialist diabetes tool toward a mainstream monitoring category, with growth supported by higher disease prevalence, better sensors and more digital care delivery.